Building a Systems Map: Applying Systems Thinking to Unhealthy Commodity Industry Influence on Public Health Policy

Document Type : Original Article

Authors

1 Department of Social and Policy Sciences, Faculty of Humanities & Social Sciences, University of Bath, Bath, UK

2 Centre of Active Lifestyles, Leeds Beckett University, Leeds, UK

3 Department for Health, Faculty of Humanities & Social Sciences, University of Bath, Bath, UK

4 School of Management, Marketing, Business & Society, University of Bath, Bath, UK

5 Department of Psychology, Faculty of Humanities & Social Sciences, University of Bath, Bath, UK

Abstract

Background 
Unhealthy commodity industries (UCIs) engage in political practices to influence public health policy, which poses barriers to protecting and promoting public health. Such influence exhibits characteristics of a complex system. Systems thinking would therefore appear to be a useful lens through which to study this phenomenon, potentially deepening our understanding of how UCI influence are interconnected with one another through their underlying political, economic and social structures. As such this study developed a qualitative systems map to depict the complex pathways through which UCIs influence public health policy and how they are interconnected with underlying structures.
 
Methods 
Online participatory systems mapping workshops were conducted between November 2021 and February 2022. As a starting point for the workshops, a preliminary systems map was developed based on recent research. Twenty-three online workshops were conducted with 52 geographically diverse stakeholders representing academia, civil society (CS), public office, and global governance organisations (CGO). Analysis of workshop data in NVivo and feedback from participants resulted in a final systems map.
 
Results 
The preliminary systems map consisted of 40 elements across six interdependent themes. The final systems map consisted of 64 elements across five interdependent themes, representing key pathways through which UCIs impact health policy-making: (1) direct access to public sector decision-makers; (2) creation of confusion and doubt about policy decisions; (3) corporate prioritisation of commercial profits and growth; (4) industry leveraging the legal and dispute settlement processes; and (5) industry leveraging policy-making, norms, rules, and processes.
 
Conclusion 
UCI influence on public health policy is highly complex, involves interlinked practices, and is not reducible to a single point within the system. Instead, pathways to UCI influence emerge from the complex interactions between disparate national and global political, economic and social structures. These pathways provide numerous avenues for UCIs to influence public health policy, which poses challenges to formulating a singular intervention or limited set of interventions capable of effectively countering such influence. Using participatory methods, we made transparent the interconnections that could help identify interventions in future work.

Keywords

References

  1. Gilmore AB, Fabbri A, Baum F, et al. Defining and conceptualising the commercial determinants of health. Lancet. 2023;401(10383):1194-1213. doi:1016/s0140-6736(23)00013-2
  2. Ulucanlar S, Lauber K, Fabbri A, et al. Corporate political activity: taxonomies and model of corporate influence on public policy. Int J Health Policy Manag. 2023;12:7292. doi:34172/ijhpm.2023.7292
  3. Knai C, Petticrew M, Capewell S, et al. The case for developing a cohesive systems approach to research across unhealthy commodity industries. BMJ Glob Health. 2021;6(2):e003543. doi:1136/bmjgh-2020-003543
  4. de Lacy-Vawdon C, Livingstone C. Defining the commercial determinants of health: a systematic review. BMC Public Health. 2020;20(1):1022. doi:1186/s12889-020-09126-1
  5. Savell E, Fooks G, Gilmore AB. How does the alcohol industry attempt to influence marketing regulations? A systematic review. Addiction. 2016;111(1):18-32. doi:1111/add.13048
  6. Wiist WH. Public health and the anticorporate movement: rationale and recommendations. Am J Public Health. 2006;96(8):1370-1375. doi:2105/ajph.2005.072298
  7. Madureira Lima J, Galea S. Corporate practices and health: a framework and mechanisms. Global Health. 2018;14(1):21. doi:1186/s12992-018-0336-y
  8. Wiist WH. The Bottom Line or Public Health: Tactics Corporations Use to Influence Health and Health Policy, and What We Can Do to Counter Them. Oxford: Oxford University Press; 2010.
  9. Freudenberg N. Lethal but Legal: Corporations, Consumption, and Protecting Public Health. Oxford University Press; 2014.
  10. Freudenberg N. The manufacture of lifestyle: the role of corporations in unhealthy living. J Public Health Policy. 2012;33(2):244-256. doi:1057/jphp.2011.60
  11. Freudenberg N, Galea S. The impact of corporate practices on health: implications for health policy. J Public Health Policy. 2008;29(1):86-104. doi:1057/palgrave.jphp.3200158
  12. Jahiel RI. Corporation-induced diseases, upstream epidemiologic surveillance, and urban health. J Urban Health. 2008;85(4):517-531. doi:1007/s11524-008-9283-x
  13. Savell E, Gilmore AB, Fooks G. How does the tobacco industry attempt to influence marketing regulations? A systematic review. PLoS One. 2014;9(2):e87389. doi:1371/journal.pone.0087389
  14. Mialon M, Swinburn B, Sacks G. A proposed approach to systematically identify and monitor the corporate political activity of the food industry with respect to public health using publicly available information. Obes Rev. 2015;16(7):519-530. doi:1111/obr.12289
  15. Mialon M, da Silva Gomes F. Public health and the ultra-processed food and drink products industry: corporate political activity of major transnationals in Latin America and the Caribbean. Public Health Nutr. 2019;22(10):1898-1908. doi:1017/s1368980019000417
  16. Mialon M, McCambridge J. Alcohol industry corporate social responsibility initiatives and harmful drinking: a systematic review. Eur J Public Health. 2018;28(4):664-673. doi:1093/eurpub/cky065
  17. Mialon M, Mialon J. Analysis of corporate political activity strategies of the food industry: evidence from France. Public Health Nutr. 2018;21(18):3407-3421. doi:1017/s1368980018001763
  18. Mialon M, Mialon J. Corporate political activity of the dairy industry in France: an analysis of publicly available information. Public Health Nutr. 2017;20(13):2432-2439. doi:1017/s1368980017001197
  19. Mialon M, Swinburn B, Allender S, Sacks G. Systematic examination of publicly-available information reveals the diverse and extensive corporate political activity of the food industry in Australia. BMC Public Health. 2016;16:283. doi:1186/s12889-016-2955-7
  20. Mialon M, Swinburn B, Wate J, Tukana I, Sacks G. Analysis of the corporate political activity of major food industry actors in Fiji. Global Health. 2016;12(1):18. doi:1186/s12992-016-0158-8
  21. Paixão MM, Mialon M. Help or hindrance? The alcohol industry and alcohol control in Portugal. Int J Environ Res Public Health. 2019;16(22):4554. doi:3390/ijerph16224554
  22. Tanrikulu H, Neri D, Robertson A, Mialon M. Corporate political activity of the baby food industry: the example of Nestlé in the United States of America. Int Breastfeed J. 2020;15(1):22. doi:1186/s13006-020-00268-x
  23. Anderson SJ. Marketing of menthol cigarettes and consumer perceptions: a review of tobacco industry documents. Tob Control. 2011;20(Suppl_2):ii20-28. doi:1136/tc.2010.041939
  24. Smith KE, Fooks G, Collin J, Weishaar H, Mandal S, Gilmore AB. "Working the system"--British American tobacco's influence on the European Union treaty and its implications for policy: an analysis of internal tobacco industry documents. PLoS Med. 2010;7(1):e1000202. doi:1371/journal.pmed.1000202
  25. Costa H, Gilmore AB, Peeters S, McKee M, Stuckler D. Quantifying the influence of the tobacco industry on EU governance: automated content analysis of the EU Tobacco Products Directive. Tob Control. 2014;23(6):473-478. doi:1136/tobaccocontrol-2014-051822
  26. Legresley E, Lee K, Muggli ME, Patel P, Collin J, Hurt RD. British American Tobacco and the "insidious impact of illicit trade" in cigarettes across Africa. Tob Control. 2008;17(5):339-346. doi:1136/tc.2008.025999
  27. Ong EK, Glantz SA. Constructing "sound science" and "good epidemiology": tobacco, lawyers, and public relations firms. Am J Public Health. 2001;91(11):1749-1757. doi:2105/ajph.91.11.1749
  28. Lawrence S, Collin J. Competing with kreteks: transnational tobacco companies, globalisation, and Indonesia. Tob Control. 2004;13(Suppl 2):ii96-103. doi:1136/tc.2004.009340
  29. Bertscher A, London L, Orgill M. Unpacking policy formulation and industry influence: the case of the draft control of marketing of alcoholic beverages bill in South Africa. Health Policy Plan. 2018;33(7):786-800. doi:1093/heapol/czy049
  30. Brownell KD, Warner KE. The perils of ignoring history: big tobacco played dirty and millions died. How similar is big food? Milbank Q. 2009;87(1):259-294. doi:1111/j.1468-0009.2009.00555.x
  31. De Vogli R, Kouvonen A, Gimeno D. The influence of market deregulation on fast food consumption and body mass index: a cross-national time series analysis. Bull World Health Organ. 2014;92(2):99-107A. doi:2471/blt.13.120287
  32. Dorfman L, Cheyne A, Friedman LC, Wadud A, Gottlieb M. Soda and tobacco industry corporate social responsibility campaigns: how do they compare? PLoS Med. 2012;9(6):e1001241. doi:1371/journal.pmed.1001241
  33. Monteiro CA, Cannon G. The impact of transnational "big food" companies on the South: a view from Brazil. PLoS Med. 2012;9(7):e1001252. doi:1371/journal.pmed.1001252
  34. Nestle M. Food Politics: How the Food Industry Influences Nutrition and Health. Berkeley: University of California Press; 2013.
  35. Ulucanlar S, Fooks GJ, Gilmore AB. The policy dystopia model: an interpretive analysis of tobacco industry political activity. PLoS Med. 2016;13(9):e1002125. doi:1371/journal.pmed.1002125
  36. Knai C, Petticrew M, Mays N, et al. Systems thinking as a framework for analyzing commercial determinants of health. Milbank Q. 2018;96(3):472-498. doi:1111/1468-0009.12339
  37. Milsom P, Smith R, Walls H. A systems thinking approach to inform coherent policy action for NCD prevention: Comment on "How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention". Int J Health Policy Manag. 2020;9(5):212-214. doi:15171/ijhpm.2019.113
  38. Nobles JD, Radley D, Mytton OT. The Action Scales Model: a conceptual tool to identify key points for action within complex adaptive systems. Perspect Public Health. 2022;142(6):328-337. doi:1177/17579139211006747
  39. Barbrook-Johnson P, Penn A. Participatory systems mapping for complex energy policy evaluation. Evaluation. 2021;27(1):57-79. doi:1177/1356389020976153
  40. Rutter H, Savona N, Glonti K, et al. The need for a complex systems model of evidence for public health. Lancet. 2017;390(10112):2602-2604. doi:1016/s0140-6736(17)31267-9
  41. Stroh DP. Systems Thinking for Social Change: A Practical Guide to Solving Complex Problems, Avoiding Unintended Consequences, and Achieving Lasting Results. Chelsea Green Publishing; 2015.
  42. The Health Foundation. Evidence Scan: Complex Adaptive Systems. London, UK: The Health Foundation; 2010.
  43. Sterman JD. Learning from evidence in a complex world. Am J Public Health. 2006;96(3):505-514. doi:2105/ajph.2005.066043
  44. Meadows DH. Thinking in Systems: A Primer. London, UK: Chelsea Green Publishing; 2008.
  45. Jebb SA, Finegood DT, Diez Roux AV, et al. Systems-Based Approaches in Public Health: Where Next? The Academy of Medical Sciences, Canadian Academy of Health Sciences; 2020.
  46. Checkland P. Systems thinking and soft systems methodology. In: Galliers RD, Currie WL, eds. The Oxford Handbook of Management Information Systems. Oxford University Press; 2011.
  47. Checkland P. Systems thinking, systems practice. In: Currie WL, Galliers B, eds. Rethinking Management Information Systems. Oxford: Oxford University Press; 1999:45-56.
  48. Carey G, Malbon E, Carey N, Joyce A, Crammond B, Carey A. Systems science and systems thinking for public health: a systematic review of the field. BMJ Open. 2015;5(12):e009002. doi:1136/bmjopen-2015-009002
  49. Peters DH. The application of systems thinking in health: why use systems thinking? Health Res Policy Syst. 2014;12:51. doi:1186/1478-4505-12-51
  50. Leischow SJ, Best A, Trochim WM, et al. Systems thinking to improve the public's health. Am J Prev Med. 2008;35(2 Suppl):S196-203. doi:1016/j.amepre.2008.05.014
  51. Kim DH. Systems Thinking Tools: A User's Reference Guide. Waltham, MA: Pegasus Communications Inc; 1994.
  52. Meadows DH. Leverage Points: Places to Intervene in a System. The Sustainability Institute; 1999.
  53. Diez Roux AV. Complex systems thinking and current impasses in health disparities research. Am J Public Health. 2011;101(9):1627-1634. doi:2105/ajph.2011.300149
  54. Johnston LM, Matteson CL, Finegood DT. Systems science and obesity policy: a novel framework for analyzing and rethinking population-level planning. Am J Public Health. 2014;104(7):1270-1278. doi:2105/ajph.2014.301884
  55. Fooks GJ, Gilmore AB. Corporate philanthropy, political influence, and health policy. PLoS One. 2013;8(11):e80864. doi:1371/journal.pone.0080864
  56. Fooks G, Gilmore A, Collin J, Holden C, Lee K. The limits of corporate social responsibility: techniques of neutralization, stakeholder management and political CSR. J Bus Ethics. 2013;112(2):283-299. doi:1007/s10551-012-1250-5
  57. Fooks GJ, Gilmore AB, Smith KE, Collin J, Holden C, Lee K. Corporate social responsibility and access to policy élites: an analysis of tobacco industry documents. PLoS Med. 2011;8(8):e1001076. doi:1371/journal.pmed.1001076
  58. Peeters S, Costa H, Stuckler D, McKee M, Gilmore AB. The revision of the 2014 European tobacco products directive: an analysis of the tobacco industry's attempts to 'break the health silo.’ Tob Control. 2016;25(1):108-117. doi:1136/tobaccocontrol-2014-051919
  59. Tobacco Tactics. Third Party Techniques. 2019. https://tobaccotactics.org/wiki/Third-Party-Techniques/. Accessed June 11, 2020.
  60. Thomas SL, David J, Randle M, Daube M, Senior K. Gambling advocacy: lessons from tobacco, alcohol and junk food. Aust N Z J Public Health. 2016;40(3):211-217. doi:1111/1753-6405.12410
  61. Hird TR, Gallagher AWA, Evans-Reeves K, et al. Understanding the long-term policy influence strategies of the tobacco industry: two contemporary case studies. Tob Control. 2022;31(2):297-307. doi:1136/tobaccocontrol-2021-057030
  62. Peeters S, Gilmore AB. Understanding the emergence of the tobacco industry's use of the term tobacco harm reduction in order to inform public health policy. Tob Control. 2015;24(2):182-189. doi:1136/tobaccocontrol-2013-051502
  63. Peeters S, Gilmore AB. Transnational tobacco company interests in smokeless tobacco in Europe: analysis of internal industry documents and contemporary industry materials. PLoS Med. 2013;10(9):e1001506. doi:1371/journal.pmed.1001506
  64. Tobacco Tactics. Harm Reduction. 2020. https://tobaccotactics.org/wiki/harm-reduction/#:~:text=A%20harm%20reduction%20approach%20to,ultimately%20quitting%20nicotine%20use%20altogether. Accessed June 12, 2020.
  65. Fitzpatrick I, Bertscher A, Gilmore AB. Identifying misleading corporate narratives: the application of linguistic and qualitative methods to commercial determinants of health research. PLOS Glob Public Health. 2022;2(11):e0000379. doi:1371/journal.pgph.0000379
  66. Tobacco Tactics. Newer Nicotine and Tobacco Products: British American Tobacco. 2022. https://tobaccotactics.org/wiki/newer-nicotine-and-tobacco-products-british-american-tobacco/. Accessed April 26, 2022.
  67. Fitzpatrick I, Dance S, Silver K, Violini M, Hird TR. Tobacco industry messaging around harm: narrative framing in PMI and BAT press releases and annual reports 2011 to 2021. Front Public Health. 2022;10:958354. doi:3389/fpubh.2022.958354
  68. Li M, Trencher G, Asuka J. The clean energy claims of BP, Chevron, ExxonMobil and Shell: a mismatch between discourse, actions and investments. PLoS One. 2022;17(2):e0263596. doi:1371/journal.pone.0263596
  69. Anderson P, Kokole D, Jané Llopis E, Burton R, Lachenmeier DW. Lower strength alcohol products-a realist review-based road map for European policy making. Nutrients. 2022;14(18):3779. doi:3390/nu14183779
  70. Thorn M. Addressing power and politics through action on the commercial determinants of health. Health Promot J Austr. 2018;29(3):225-227. doi:1002/hpja.216
  71. Milsom P, Smith R, Baker P, Walls H. Corporate power and the international trade regime preventing progressive policy action on non-communicable diseases: a realist review. Health Policy Plan. 2021;36(4):493-508. doi:1093/heapol/czaa148
  72. Wood B, Baker P, Sacks G. Conceptualising the commercial determinants of health using a power lens: a review and synthesis of existing frameworks. Int J Health Policy Manag. 2022;11(8):1251-1261. doi:34172/ijhpm.2021.05
  73. McKee M, Stuckler D. Revisiting the corporate and commercial determinants of health. Am J Public Health. 2018;108(9):1167-1170. doi:2105/ajph.2018.304510
  74. Wood B, Williams O, Nagarajan V, Sacks G. Market strategies used by processed food manufacturers to increase and consolidate their power: a systematic review and document analysis. Global Health. 2021;17(1):17. doi:1186/s12992-021-00667-7
  75. Wood B, Williams O, Baker P, Nagarajan V, Sacks G. The influence of corporate market power on health: exploring the structure-conduct-performance model from a public health perspective. Global Health. 2021;17(1):41. doi:1186/s12992-021-00688-2
  76. Lacy-Nichols J, Marten R. Power and the commercial determinants of health: ideas for a research agenda. BMJ Glob Health. 2021;6(2):e003850. doi:1136/bmjgh-2020-003850
  77. Barlow P, Thow AM. Neoliberal discourse, actor power, and the politics of nutrition policy: a qualitative analysis of informal challenges to nutrition labelling regulations at the World Trade Organization, 2007-2019. Soc Sci Med. 2021;273:113761. doi:1016/j.socscimed.2021.113761
  78. Townsend B, Schram A, Labonté R, Baum F, Friel S. How do actors with asymmetrical power assert authority in policy agenda-setting? A study of authority claims by health actors in trade policy. Soc Sci Med. 2019;236:112430. doi:1016/j.socscimed.2019.112430
  79. Sula-Raxhimi E, Butzbach C, Brousselle A. Planetary health: countering commercial and corporate power. Lancet Planet Health. 2019;3(1):e12-e13. doi:1016/s2542-5196(18)30241-9
  80. Kentikelenis A, Rochford C. Power asymmetries in global governance for health: a conceptual framework for analyzing the political-economic determinants of health inequities. Global Health. 2019;15(Suppl 1):70. doi:1186/s12992-019-0516-4
  81. Battams S, Townsend B. Power asymmetries, policy incoherence and noncommunicable disease control - a qualitative study of policy actor views. Crit Public Health. 2019;29(5):596-609. doi:1080/09581596.2018.1492093
  82. Abdul Mu’eez AS, Arifah AR, Azreena MB, Farahana MP, Mustafa AD, Juni MH. Agenda setting and power in policy making: a case study of tobacco policy in developing countries. Int J Public Health Clin Sci. 2018;5(3):1-16.
  83. Pechlaner G, Otero G. The neoliberal food regime: neoregulation and the new division of labor in North America. Rural Sociol. 2010;75(2):179-208. doi:1111/j.1549-0831.2009.00006.x
  84. Lencucha R, Thow AM. How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention. Int J Health Policy Manag. 2019;8(9):514-520. doi:15171/ijhpm.2019.56
  85. Otero G. The neoliberal food regime in Latin America: state, agribusiness transnational corporations and biotechnology. Rev Can Etudes Dev. 2012;33(3):282-294. doi:1080/02255189.2012.711747
  86. Parker LA, Zaragoza GA, Hernández-Aguado I. Promoting population health with public-private partnerships: where's the evidence? BMC Public Health. 2019;19(1):1438. doi:1186/s12889-019-7765-2
  87. Erzse A, Karim SA, Foley L, Hofman KJ. A realist review of voluntary actions by the food and beverage industry and implications for public health and policy in low- and middle-income countries. Nat Food. 2022;3(8):650-663. doi:1038/s43016-022-00552-5
  88. Mialon M, Vandevijvere S, Carriedo-Lutzenkirchen A, et al. Mechanisms for addressing and managing the influence of corporations on public health policy, research and practice: a scoping review. BMJ Open. 2020;10(7):e034082. doi:1136/bmjopen-2019-034082
  89. Mialon M. An overview of the commercial determinants of health. Global Health. 2020;16(1):74. doi:1186/s12992-020-00607-x
  90. Lacy-Nichols J, Marten R, Crosbie E, Moodie R. The public health playbook: ideas for challenging the corporate playbook. Lancet Glob Health. 2022;10(7):e1067-e1072. doi:1016/s2214-109x(22)00185-1
  91. Friel S, Collin J, Daube M, et al. Commercial determinants of health: future directions. Lancet. 2023;401(10383):1229-1240. doi:1016/s0140-6736(23)00011-9
  92. Labonté R. Neoliberalism 4.0: the rise of illiberal capitalism: Comment on "How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention". Int J Health Policy Manag. 2020;9(4):175-178. doi:15171/ijhpm.2019.111
  93. Willis CD, Mitton C, Gordon J, Best A. System tools for system change. BMJ Qual Saf. 2012;21(3):250-262. doi:1136/bmjqs-2011-000482
  94. Williams B, Hummelbrunner R. Systems Concepts in Action: A Practitioner's Toolkit. Stanford University Press; 2010.
  95. Barbrook-Johnson P, Penn AS. Systems Mapping: How to Build and Use Causal Models of Systems. Cham, Switzerland: Palgrave Macmillan; 2022.
  96. World Health Organization (WHO). Global Status Report on Noncommunicable Diseases 2014. Geneva: WHO; 2014.
  97. World Health Organization (WHO). Four Noncommunicable Diseases, Four Shared Risk Factors. https://www.who.int/ncdnet/about/4diseases/en/. Accessed July 21, 2020.
  98. World Health Organization (WHO). Noncommunicable Diseases Country Profiles 2018. Geneva: WHO; 2018.
  99. World Health Organization (WHO). Noncommunicable Diseases. 2018. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed June 9, 2020.
  100. Burke JG, O'Campo P, Peak GL, Gielen AC, McDonnell KA, Trochim WM. An introduction to concept mapping as a participatory public health research method. Qual Health Res. 2005;15(10):1392-1410. doi:1177/1049732305278876
  101. Trani JF, Ballard E, Bakhshi P, Hovmand P. Community based system dynamic as an approach for understanding and acting on messy problems: a case study for global mental health intervention in Afghanistan. Confl Health. 2016;10:25. doi:1186/s13031-016-0089-2
  102. Glenn J, Kamara K, Umar ZA, Chahine T, Daulaire N, Bossert T. Applied systems thinking: a viable approach to identify leverage points for accelerating progress towards ending neglected tropical diseases. Health Res Policy Syst. 2020;18(1):56. doi:1186/s12961-020-00570-4
  103. Legg T, Hatchard J, Gilmore AB. The science for profit model-how and why corporations influence science and the use of science in policy and practice. PLoS One. 2021;16(6):e0253272. doi:1371/journal.pone.0253272
  104. Kurnaz FB, Ergün E, Ilgaz H. Participation in online discussion environments: is it really effective? Educ Inf Technol. 2018;23(4):1719-1736. doi:1007/s10639-018-9688-4
  105. Chavez-Ugalde Y, Toumpakari Z, White M, De Vocht F, Jago R. Using group model building to frame the commercial determinants of dietary behaviour in adolescence - proposed methods for online system mapping workshops. BMC Med Res Methodol. 2022;22(1):84. doi:1186/s12874-022-01576-y
  106. Causal Mapping with Seed Structure. 2013. https://en.wikibooks.org/wiki/Scriptapedia/Causal_Mapping_with_Seed_Structure. Accessed April 27, 2022.
  107. Andersen DF, Calhoun A, Hovmand PS, et al. Scriptapedia. 2021. https://en.wikibooks.org/wiki/Scriptapedia. Accessed April 27, 2022.
  108. Campbell S, Greenwood M, Prior S, et al. Purposive sampling: complex or simple? Research case examples. J Res Nurs. 2020;25(8):652-661. doi:1177/1744987120927206
  109. Smith KE, Fooks G, Gilmore AB, Collin J, Weishaar H. Corporate coalitions and policy making in the European Union: how and why British American Tobacco promoted "better regulation". J Health Polit Policy Law. 2015;40(2):325-372. doi:1215/03616878-2882231
  110. Chandler J, Rycroft-Malone J, Hawkes C, Noyes J. Application of simplified complexity theory concepts for healthcare social systems to explain the implementation of evidence into practice. J Adv Nurs. 2016;72(2):461-480. doi:1111/jan.12815
  111. Keshavarz N, Nutbeam D, Rowling L, Khavarpour F. Schools as social complex adaptive systems: a new way to understand the challenges of introducing the health promoting schools concept. Soc Sci Med. 2010;70(10):1467-1474. doi:1016/j.socscimed.2010.01.034
  112. Rickles D, Hawe P, Shiell A. A simple guide to chaos and complexity. J Epidemiol Community Health. 2007;61(11):933-937. doi:1136/jech.2006.054254
  113. Bonell C, Jamal F, Melendez-Torres GJ, Cummins S. 'Dark logic': theorising the harmful consequences of public health interventions. J Epidemiol Community Health. 2015;69(1):95-98. doi:1136/jech-2014-204671
  114. Linz JJ. Totalitarian and Authoritarian Regimes. Lynne Rienner Publishers; 2000.
  115. Fukuyama F. Liberal democracy as a global phenomenon. PS Polit Sci Polit. 1991;24(4):659-664. doi:2307/419399
  116. Schrecker T, Bambra C. How Politics Makes Us Sick: Neoliberal Epidemics. Springer; 2015.
  117. Harvey D. A Brief History of Neoliberalism. USA: Oxford University Press; 2007.
  118. Chang HJ. 23 Things They Don't Tell You About Capitalism. USA: Bloomsbury Publishing; 2012.
  119. Hickel J, Kallis G. Is green growth possible? New Political Econ. 2020;25(4):469-486. doi:1080/13563467.2019.1598964
  120. Stockmann D. Media Commercialization and Authoritarian Rule in China. Cambridge University Press; 2013.
  121. Lencucha R, Thow AM. Intersectoral policy on industries that produce unhealthy commodities: governing in a new era of the global economy? BMJ Glob Health. 2020;5(8):e002246. doi:1136/bmjgh-2019-002246
  122. Herrick C. On the perils of universal and product-led thinking: Comment on "How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention". Int J Health Policy Manag. 2020;9(5):209-211. doi:15171/ijhpm.2019.109
  123. Krzyżanowski M. Normalization and the discursive construction of “new” norms and “new” normality: discourse in the paradoxes of populism and neoliberalism. Soc Semiot. 2020;30(4):431-448. doi:1080/10350330.2020.1766193
  124. Lee K, Crosbie E. Understanding structure and agency as commercial determinants of health: Comment on "How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention". Int J Health Policy Manag. 2020;9(7):315-318. doi:15171/ijhpm.2019.127
  125. Schram A, Goldman S. Paradigm shift: new ideas for a structural approach to NCD prevention: Comment on "How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention". Int J Health Policy Manag. 2020;9(3):124-127. doi:15171/ijhpm.2019.105
  126. Smith J. Towards critical analysis of the political determinants of health: Comment on "How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention". Int J Health Policy Manag. 2020;9(3):121-123. doi:15171/ijhpm.2019.102
  127. Townsend B. Next steps for elevating health on trade and investment policy agendas: Comment on "How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention". Int J Health Policy Manag. 2020;9(7):312-314. doi:15171/ijhpm.2019.126
  128. Battams S. Neo-Liberalism, Policy incoherence and discourse coalitions influencing non-communicable disease strategy: Comment on "How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention". Int J Health Policy Manag. 2020;9(3):116-118. doi:15171/ijhpm.2019.95
  129. Glasgow S, Schrecker T. The double burden of neoliberalism? Noncommunicable disease policies and the global political economy of risk. Health Place. 2015;34:279-286. doi:1016/j.healthplace.2015.06.005
  130. Collin J. Tobacco control, global health policy and development: towards policy coherence in global governance. Tob Control. 2012;21(2):274-280. doi:1136/tobaccocontrol-2011-050418
  131. Lencucha R, Drope J, Chavez JJ. Whole-of-government approaches to NCDs: the case of the Philippines Interagency Committee-Tobacco. Health Policy Plan. 2015;30(7):844-852. doi:1093/heapol/czu085
  132. Blouin C. Trade policy and health: from conflicting interests to policy coherence. Bull World Health Organ. 2007;85(3):169-173. doi:2471/blt.06.037413
  133. Raworth K. Doughnut Economics: Seven Ways to Think Like a 21st-Century Economist. Chelsea Green Publishing; 2017.
  134. Hickel J. Less is More: How Degrowth Will Save the World. Random House; 2020.
  135. Moodie R, Stuckler D, Monteiro C, et al. Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet. 2013;381(9867):670-679. doi:1016/s0140-6736(12)62089-3
  136. Room R, Gleeson D, Miller M. Alcoholic beverages in trade agreements: industry lobbying and the public health interest. Drug Alcohol Rev. 2021;40(1):19-21. doi:1111/dar.13214
  137. Milsom P, Smith R, Baker P, Walls H. International investment liberalization, transnational corporations and NCD prevention policy non-decisions: a realist review on the political economy of tobacco, alcohol and ultra-processed food. Global Health. 2021;17(1):134. doi:1186/s12992-021-00784-3
  138. Hawkins B, Holden C, Eckhardt J, Lee K. Reassessing policy paradigms: a comparison of the global tobacco and alcohol industries. Glob Public Health. 2018;13(1):1-19. doi:1080/17441692.2016.1161815
  139. Schram A, Townsend B. International trade and investment and food systems: what we know, what we don't know, and what we don't know we don't know. Int J Health Policy Manag. 2021;10(12):886-895. doi:34172/ijhpm.2020.202
  140. Miller M, Wilkinson C, Room R, et al. Industry submissions on alcohol in the context of Australia's trade and investment agreements: a content and thematic analysis of publicly available documents. Drug Alcohol Rev. 2021;40(1):22-30. doi:1111/dar.13219
  141. Gleeson D, Friel S. Emerging threats to public health from regional trade agreements. Lancet. 2013;381(9876):1507-1509. doi:1016/s0140-6736(13)60312-8
  142. Eastmure E, Cummins S, Sparks L. Non-market strategy as a framework for exploring commercial involvement in health policy: a primer. Soc Sci Med. 2020;262:113257. doi:1016/j.socscimed.2020.113257
  143. Baum FE, Sanders DM, Fisher M, et al. Assessing the health impact of transnational corporations: its importance and a framework. Global Health. 2016;12(1):27. doi:1186/s12992-016-0164-x
  144. Labonté R, Schrecker T. Globalization and social determinants of health: the role of the global marketplace (part 2 of 3). Global Health. 2007;3:6. doi:1186/1744-8603-3-6
  145. Ramos AK. Child labor in global tobacco production: a human rights approach to an enduring dilemma. Health Hum Rights. 2018;20(2):235-248.
  146. Sheikh ZD, Branston JR, Gilmore AB. Tobacco industry pricing strategies in response to excise tax policies: a systematic review. Tob Control. 2023;32(2):239-250. doi:1136/tobaccocontrol-2021-056630
  147. Bennett R, Zorbas C, Huse O, et al. Prevalence of healthy and unhealthy food and beverage price promotions and their potential influence on shopper purchasing behaviour: a systematic review of the literature. Obes Rev. 2020;21(1):e12948. doi:1111/obr.12948
  148. Gechert S, Heimberger P. Do corporate tax cuts boost economic growth? Eur Econ Rev. 2022;147:104157. doi:1016/j.euroecorev.2022.104157
  149. Tax Justice Network. Tax avoidance and evasion-The scale of the problem. Tax Justice Network; 2017.
  150. UNEP, UNDP, FAO. A Multi-Billion-Dollar Opportunity: Repurposing Agricultural Support to Transform Food Systems. Food and Agriculture Organization; 2021.
  151. Anderson K, Meloni G, Swinnen J. Global alcohol markets: evolving consumption patterns, regulations, and industrial organizations. Annu Rev Resour Economics. 2018;10:105-132. doi:1146/annurev-resource-100517-023331
  152. Blecher E, Bertram M. The economics and control of tobacco, alcohol, food products, and sugar-sweetened beverages. In: Vaccarella S, Lortet-Tieulent J, Saracci R, Conway DI, Straif K, Wild CP, eds. Reducing Social Inequalities in Cancer: Evidence and Priorities for Research. Lyon, FR: International Agency for Research on Cancer; 2019.
  153. Lauber K, Ralston R, Mialon M, Carriedo A, Gilmore AB. Non-communicable disease governance in the era of the sustainable development goals: a qualitative analysis of food industry framing in WHO consultations. Global Health. 2020;16(1):76. doi:1186/s12992-020-00611-1
  154. Lauber K, Rutter H, Gilmore AB. Big food and the World Health Organization: a qualitative study of industry attempts to influence global-level non-communicable disease policy. BMJ Glob Health. 2021;6(6):e005216. doi:1136/bmjgh-2021-005216
  155. Lauber K, McGee D, Gilmore AB. Commercial use of evidence in public health policy: a critical assessment of food industry submissions to global-level consultations on non-communicable disease prevention. BMJ Glob Health. 2021;6(8):e006176. doi:1136/bmjgh-2021-006176
  156. Zhou S, Ricafort E, Bressler D, Devotsu RK. Litigation in tobacco control: past, present and future. Tob Control. 2022;31(2):291-295. doi:1136/tobaccocontrol-2021-056561
  157. Roache SA, Platkin C, Gostin LO, Kaplan C. Big food and soda versus public health: industry litigation against local government regulations to promote healthy diets. Fordham Urban Law J. 2017;45(4):1051-1089.
  158. Hawkins B, Holden C. A corporate veto on health policy? Global constitutionalism and investor-state dispute settlement. J Health Polit Policy Law. 2016;41(5):969-995. doi:1215/03616878-3632203
  159. Milsom P, Smith R, Modisenyane SM, Walls H. Do international trade and investment agreements generate regulatory chill in public health policymaking? A case study of nutrition and alcohol policy in South Africa. Global Health. 2021;17(1):104. doi:1186/s12992-021-00757-6
  160. Ulucanlar S, Fooks GJ, Hatchard JL, Gilmore AB. Representation and misrepresentation of scientific evidence in contemporary tobacco regulation: a review of tobacco industry submissions to the UK government consultation on standardised packaging. PLoS Med. 2014;11(3):e1001629. doi:1371/journal.pmed.1001629
  161. Berry C, Devlin S. Threat to Democracy: The Impact of ‘Better Regulation’ in the UK. London: New Economics Foundation; 2008.
  162. Boaz A, Hanney S, Borst R, O'Shea A, Kok M. How to engage stakeholders in research: design principles to support improvement. Health Res Policy Syst. 2018;16(1):60. doi:1186/s12961-018-0337-6
  163. Jacobson D, Mustafa N. Social Identity Map: A reflexivity tool for practicing explicit positionality in critical qualitative research. Int J Qual Methods. 2019;18:1609406919870075. doi:1177/1609406919870075

Files

History

  • Receive Date: 08 December 2022
  • Revise Date: 24 October 2023
  • Accept Date: 12 March 2024
  • First Publish Date: 13 March 2024

Share

How to cite

Statistics